bevacizumab + capecitabine + dasatinib + oxaliplatin

This is a four-drug investigational combination regimen consisting of bevacizumab, capecitabine, dasatinib, and oxaliplatin. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) essential for tumor growth. - **Capecitabine** is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in tumors, where it acts as an antimetabolite inhibiting DNA synthesis and cell proliferation[4]. - **Dasatinib** is a small molecule tyrosine kinase inhibitor targeting multiple kinases including the Src family kinases; it has both anti-proliferative and anti-angiogenic properties[2][6]. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that induces cytotoxicity primarily through DNA crosslinking, leading to apoptosis of rapidly dividing cells[5]. This combination has been studied in phase I trials for advanced solid tumors and metastatic colorectal cancer with the aim of determining safety, tolerability, and preliminary efficacy. The rationale includes potential synergistic effects by combining antiangiogenic therapy with cytotoxic chemotherapy and targeted inhibition of Src signaling pathways[2][6][8].

Other names

XAD